PFE News Alert Pfizer Inc (PFE) 31.42 12/25/2014 16:23:22

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 31.42 $PFE

Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST

MNK: 97.84 (-0.29), BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

Most active New York Stock Exchange-traded stocks
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
TLM.TO: 9.10 (-0.01), GE: 25.83 (-0.05), ABX.TO: 12.02 (+0.21), TLM: 7.84 (unch), K.TO: 3.13 (+0.11), ABX: 10.31 (+0.14), S: 4.19 (-0.05), KGC: 2.70 (+0.11), PFE: 31.42 (-0.03), BAC: 17.98 (+0.05), ORCL: 46.23 (+0.22), RAD: 7.26 (-0.09)

Final Glance: Pharmaceuticals companies
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)

Early Glance: Pharmaceuticals companies
AP - Wed Dec 24, 9:23AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)

Pfizer's Immunology Pipeline Has Few Bright Spots Besides Xeljanz
Clinically Sound Investor - at Seeking Alpha - Wed Dec 24, 9:21AM CST

PFE: 31.42 (-0.03)

3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.10 (+0.34), INO: 9.11 (-0.09), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), AUXL: 34.40 (+0.18), VVUS: 2.99 (-0.02), TEVA: 57.09 (+0.33), ARNA: 3.57 (-0.01)

Look for Shares of Pfizer to Potentially Rebound after Yesterday's 1.99% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 3:42PM CST
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $30.77 to a high of $32.22. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $31.42 on volume of 33.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 31.42 (-0.03)

After Yesterday's Decline of 1.99%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 23, 3:41PM CST
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $30.77 to a high of $32.22. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $31.42 on volume of 33.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 31.42 (-0.03)

Microsoft, Google Lead Tech Firms With The Most Cash
at Investor's Business Daily - Tue Dec 23, 1:29PM CST
If cash is king, then the information technology sector gets the crown -- and it's a big one. Led by Microsoft (MSFT), tech companies in the S&P 500 accounted for 37% of the $1.37 trillion in cash and short-term investments held at the end of the...
JNJ: 104.59 (+0.31), F: 15.30 (-0.03), GE: 25.83 (-0.05), MON: 120.97 (-1.70), PFE: 31.42 (-0.03), GOOGL: 536.93 (-1.84), MSFT: 48.14 (-0.31), AAPL: 112.01 (-0.53), ORCL: 46.23 (+0.22), CSCO: 28.30 (+0.05)

Midday Glance: Pharmaceuticals companies
AP - Tue Dec 23, 12:22PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)

Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST

AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)

Indexes Turn Mixed On Data; Celgene Dives
at Investor's Business Daily - Tue Dec 23, 9:43AM CST
Stocks backed off early gains and were mixed early Tuesday as investors wrestled through a jumble of economic news. The Dow Jones industrial average rose 0.4% and the S&P 500 added 0.2% as both indexes reached new highs. The Nasdaq shed its early...
DDS: 122.53 (+0.53), BIIB: 340.89 (+5.13), JNJ: 104.59 (+0.31), ABG: 77.12 (+0.43), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), CELG: 109.60 (+3.48)

PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST

ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)

It's Official: Zoetis Belongs In Your Dividend Growth Portfolio
DG Ruralist - at Seeking Alpha - Mon Dec 22, 3:46PM CST

ZTS: 43.84 (+0.87), PFE: 31.42 (-0.03)

Wall Street Breakfast: China Offers Support For Russia's Currency Crisis
Wall Street Breakfast - Seeking Alpha - Mon Dec 22, 5:29AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Long Top Idea...
AMX: 21.98 (-0.01), FRPT: 15.30 (+1.07), OCN: 14.88 (-0.14), PFE: 31.42 (-0.03), BNFT: 32.78 (+0.75), SNE: 21.32 (+0.46), CZR: 15.44 (+0.20), XL: 34.26 (-0.11), CACQ: 9.96 (+0.12), T: 33.96 (-0.07), JNJ: 104.59 (+0.31), APP: 1.06 (+0.01), ESRX: 85.48 (-0.40), SPY: 207.77 (+0.02), QQQ: 104.30 (+0.09), GILD: 91.29 (+1.84), AZN: 70.44 (+0.26), GM: 33.43 (-0.13), MDW: 0.63 (+0.03), ABBV: 66.21 (+1.86)

The Most Disappointing Clinical Failures in 2014
Motley Fool Staff - Motley Fool - Sun Dec 21, 6:32PM CST
Since roughly 90% of all clinical trials end in a failure, it isn't too shocking that 2014 boasted its fair share of clinical trial disappointments. But while failure is common and expected in the industry, some defeats were more disappointing than...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), EXEL: 1.29 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 146

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 139

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 66

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Raises Price Target for Blackstone Amid Encouraging Outlook

Updated Category News Views 131

Citi's Updated Outlook on Blackstone Recently, Citi revisited its financial forecast for The Blackstone Group (NYSE: BX), adjusting the price target upward from $157.00 to $170.00 while maintaining a Neutral stance on the stock. This update follows the company's impressive third-quarter performance, which saw Blackstone's stock rise by 6.3% post-earnings announcement....

Continue Reading
JAB's Strategic Acquisition of Mondelez Shares in JDE Peet's

Updated Category News Views 92

JAB's Significant Move in the Coffee Industry In a strategic and noteworthy development, JAB has made headlines by agreeing to acquire a substantial share package from Mondelez, focusing on Dutch coffee giant JDE Peet's. This major transaction amounts to approximately €2.2 billion, or about $2.4 billion. JAB intends to purchase 86 million shares at a price of €25.10...

Continue Reading
Urgent Update for DXC Technology Company Investors

Updated Category News Views 272

DXC Technology Company (NYSE: DXC) found itself in hot water back in 2024 when shareholders raised hell over alleged falsehoods that inflated stock prices. The Rosen Law Firm rolled out a class action lawsuit aimed at those who bought shares during what they dubbed the Class Period—a time rife with questionable operational claims from DXC's brass. Allegations Surface:...

Continue Reading
Investigation Launched: National Grid Faces Legal Scrutiny

Updated Category News Views 283

Bragar Eagel & Squire, P.C. Initiates Investigation Bragar Eagel & Squire, P.C., a well-regarded law firm known for advocating for investors, has begun an investigation surrounding concerns related to National Grid plc (NYSE: NGG). This inquiry primarily aims to assist stockholders who may have experienced losses while owning shares of National Grid. The firm invites...

Continue Reading
Oil & Gas Sector Trends: Path to 8.79 Trillion Growth

Updated Category News Views 223

Oil & Gas Market Growth and Projections The global oil and gas market has positioned itself for remarkable expansion. With estimates currently valuing the market at approximately USD 6.10 trillion, projections suggest it could soar to around USD 8.79 trillion by 2034. This growth translates to a compound annual growth rate (CAGR) of 3.72% between 2025 and 2034. Notably,...

Continue Reading